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1. General 
All chemicals and solvents purchased from Sigma-Aldrich were used without further purification. 
Spectra of
 1
H NMR and 
13
C NMR were recorded using a Bruker DPX-400 in CDCl3 with TMS as internal 
reference. Splitting in the spectra are shown as s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), dd (doublet of doublet), and br (broad). 
Absorption spectrometry was performed using a Varian spectrophotometer. Steady state fluorescence 
measurements were conducted using a Varian Eclipse spectrofluorometer. Column chromatography of all 
products was performed using Merck Silica Gel 60 (particle size: 0.040–0.063 mm, 230–400 mesh 
ASTM). Reactions were monitored by thin layer chromatography using fluorescent coated aluminum 
sheets. Solvents used for spectroscopy experiments were spectrophotometric grade. Mass spectrometry 
measurements were done at the Ohio State University Mass Spectrometry and Proteomics Facility, Ohio, 
U.S.A. For compounds 1, 8 and 10, mass spectra were recorded on Agilent Technologies 6530 Accurate-
Mass Q-TOF LC/MS. 
Quantum yield measurements and calculations were done using Rhodamine G6 (excitation 488 nm, 
water), Sulforhodamine 101(excitation 550 nm, ethanol) and Cresyl Violet (excitation 610 nm, methanol) 
as standard chromophores having quantum yields 0.95, 0.90 and 0.66 respectively. All absorbance values 
were below 0.1 to avoid self quenching. Following formula was used for calculations: 
1 
                Q = QR (I/IR)*(AR/A)*(n
2
/nR
2
)     
 
where QR stands for quantum yield of reference, I and IR for integrated area of emission spectrum for 
specific wavelength for sample and for standard respectively, A and AR represents absorbance of 
corresponding wavelength for sample and standard, n and nR refer to refractive indices of solvents in 
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which sample and standard compounds were dissolved respectively.  Refractive index values were taken 
to be 1.333 for water, 1.3624 for ethanol and 1.329 for methanol. All samples except standards were 
dissolved in chloroform which has an n value of 1.49.  
 Lifetime measurements were done on a HORIBA Jobin Yvon fluorolog, FL-1057. The dye laser 
excitation was at 495, 609 and 667 nm NanoLED with pulse width less than 250 ps. The instrument 
response function was measured with an aqueous Ludox solution.  The decays were analyzed with a 
multiexponential fitting function by iterative reconvolution and chi-square minimization. Results having 
χ
2
’s at around 1.0 were taken into consideration. 
 FRET efficiency was determined using time-resolved approach. Time resolved approach provides 
more accurate results since inner filter effect or errors associated with integration are lacking here.  FRET 
rate constant and FRET efficiencies were calculated using formulas below:
2, 3
 
    kFRET = 1/τDA-1/τD            
       εFRET = 1- τDA/τD  
where τD and τDA refer to excited state decay time (lifetime) of donor in the absence and presence of 
acceptor respectively. For energy transfer from mono-styryl BODIPY steady state approach with 
following formula was used. εFRET was calculated from quantum yields.  
    kFRET = 1/τD [(1/εFRET)-1]
-1
 
 
2. Theoretical Calculations 
 We describe the coupled dynamics of the photon field and luminescent centers using a simplified 
model in terms of rate equations. Three optical centers absorb and emit from the photon density at a 
particular location as described below 
 
    Eq.S1 
   Eq. S2 
 
    Eq. S3 
 
 
   Eq. S4 
Here, P(λ) shows the wavelength dependent photon number guided in the slab; n1, n2 and n3 denote the 
number of excited centers; a1, a2 and a3 denote absorption coefficients of corresponding centers; e1(λ), 
e2(λ)  and e3(λ)  denote the spectral distribution of light emission. The slab is being excited by an external 
light field with spectral distribution Pin(λ) and ηt ~ 0.75 denotes the efficiency of emission into guided 
modes of the slab. The excitation is modeled as Pin(λ) = Plaser if x=0, and Pin(λ) = 0 otherwise.  The 
luminescence and near field energy transfer efficiencies are characterized by rates  re,1,re,2,re,3 and rF,1-2, 
rF,2-3. Non-radiative losses are characterized by the rates rl,1,rl,2,rl,3 . The Monte-Carlo simulation is based 
on Eqs. S1, S2, S3, S4 using Gaussian emission and absorption profiles for individual centers. A narrow 
spectral distribution Pin(λ) with a peak around 532 nm and 2 nm spectral width is used to model the laser 
excitation. Propagation of emitted light is approximated by an average propagation direction parallel to 
the horizontal axis. In the calculation of the spectra, multiple absorption/emission events occurring not 
between the excitation and collection points are ignored for sake of simplicity. 
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Figure S1. The luminescent centers interact with photon field inside the slab light-guide, as well as with the external excitation. 
The photon field is characterized by a distribution of energy to wavelengths and wavevectors (directions) as a function of 
distance. Simplified rate equations describe the dynamics of energy transfer between the photon field and luminescent centers 
due to absorption, emission and near-field energy transfer effects. In the schematic, non-radiative losses and losses due to 
escape from the slab are omitted for clarity. 
3. Results 
 Fluorescence intensities of energy transfer cassettes and corresponding elements with equal 
absorbance at point of excitation were compared. For ET-1 quenching of donor BODIPY and increase in 
acceptor distyryl BODIPY emission was shown in Figure 1 and 2, which indicates efficient energy 
transfer. Excitation at two different wavelengths (525 nm, 585 nm) were compared in Figure 3.  
 
  
Figure S2. Absorbance spectra of compounds B1  (dashed), C1 (dot) and ET-1 (solid).  
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Figure S3. Emission spectra of compounds B1 (dashed), C1 (dot) and ET-1 (solid) with equal absorbance excited at 525 nm.  
 
Figure S4. Comparison of emissions of ET-1 excited at 525(solid line) and 585 nm (dashed line). 
 
                For ET-2 quenching of donor monostyryl-BODIPY and increase in acceptor distyryl BODIPY 
emission was shown in Figure 4 and 5, which indicates efficient channeling of energy to acceptor 
chromophore. Excitations at two different wavelengths (585 nm, 645 nm) were compared in Figure 6. 
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Figure S5. Absorbance spectra of compounds D1 (dot), C2 (dashed), ET-2 (solid).  
 
 
Figure S6. Emission spectra of compounds D1 (dot), C2 (dashed) and ET-2 (solid) with equal absorbance excited at 585 nm.  
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Figure S7. Comparison of emission of ET-2  excited at 585 nm (solid) and 645 nm (dashed). 
 
 For ET-3 decrease in donor monostyryl-BODIPY and increase in acceptor distyryl BODIPY 
emission was shown in Figure 7 and 8. Excitations at two different wavelengths (585 nm, 645 nm) were 
compared in Figure 9. 
 
Figure S8. Absorbance spectra of D2(dot), C2 (dashed), ET-2 (solid). 
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Figure S9. Emission spectra of compounds D2 (dot), C2 (dashed), ET-2 (solid) with equal absorbance excited at 585 nm. 
 
Figure S10. Comparison of emission of ET-3 excited at 585 nm (solid line), 645 nm (dashed line). 
 
 For SC-1 decrease in donor BODIPY, monostyryl-BODIPY and increase in acceptor distyryl 
BODIPY emission was shown in Figure 10, 11 and 12. Excitations at three different wavelengths (525 
nm, 585 nm, 645 nm) were compared in Figure 13. 
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Figure S11.  Absorbance spectra of compounds B1 (dashed), C2 (dot), D2 (dot-dashed), SC-1 (solid). 
 
 
 
Figure S12. Emission spectra of compounds B1 (solid), D2 (dot), SC-1 (dashed) with equal absorbance excited at 525 nm. 
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Figure S13. Emission spectra of compounds C1 (dashed), D2 (dot), SC-1 (solid) with equal absorbance excited at 585 nm. 
 
Figure S14. Comparison of emission of SC-1 excited at 525 nm (solid), 585 nm (dashed) and 645 nm (dot). 
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4. Synthesis  
4.1 Synthesis of 4-(6-bromohexoxy)benzaldehyde (1) 
 
4-hydroxybenzaldehyde (5 g, 41 mmol) and 1, 6 dibromohexane (2 g, 82 mmol) were dissolved in 
acetone (150 ml). K2CO3 (17.2 g, 123 mmol) and catalytic amount of benzo-18-crown-6 were added. The 
reaction mixture was refluxed for 12h. Then, acetone was evaporated in vacuo and extracted with water 
and chloroform. Organic layer was dried with Na2SO4 and evaporated in vacuo. The product was purified 
by silica gel column chromatography using CHCl3/Hexane (75:25, v/v). Fraction containing compound 1 
was collected then the solvent was removed under reduced pressure (6.7 mmol, 1.906 g, 16%). 
  
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.35 (m, 4H), 1.65 (m, 4H), 3.4 (t, J= 6.68 Hz, 2H),  3.88 (t, J= 6.4 
Hz, 2H), 6. 82 (d, J= 8.76 Hz, 2H), 7.68 (d, J= 8.64 Hz, 2H), 9.7 (s, 1H). 
13
C NMR (CDCl3, 100 MHz, 
δ ppm) 25.24, 26.51, 28.83, 32.39, 44.91, 68.09, 114.68, 129.73, 131.86, 164.08, 190.58. HRMS (TOF-
ESI): m/z calcd for C13H17BrO2: 285.04902 [M+H]
+
; found: 285.05413 [M+H]
+
, ∆ = 17.9 ppm. 
 
4.2 Synthesis of Compound 2 
 
CH2Cl2 (300 ml) was purged with Ar for 30 min. 4-(6-bromohexoxy)benzaldehyde 1 (1.089 g, 
3.82 mmol) and 2,4-dimethyl pyrrole (0.94 g, 7.7 mmol) were added. The color of the solution turned into 
red after the addition of 3 drops of trifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 12h. Then, tetrachloro-1,4-benzoquinone (0.93 g, 3.82 mmol) was added and the reaction 
mixture was stirred at room temperature for 45 min. Then triethyl amine (8 ml) and boron trifluoride 
diethyl etherate (8 ml) were added sequencially. After stirring at room temperature for 30 min, it was 
extracted with water. Organic layer was dried with Na2SO4 and evaporated  under reduced pressure. The 
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product was purified by silica gel column chromatography using CHCl3 as mobile phase. Fraction 
containing compound 2 was collected then the solvent was removed under reduced pressure (670 mg, 1.2 
mmol, 31% ).  
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52, 6H), 1.35 (s, 6H), 1.58 (m, 4H), 1.85 (m, 4H), 2.3 (q, 
J= 7.56,  4H), 2.55 (s, 6H), 3.59 (t, J= 6.64 Hz, 2H),  4.05 (t, J= 6.45 Hz, 2H), 7.0 (d, J= 8.56 Hz, 2H), 
7.15 (d, J= 8.56 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, δ ppm) 11.84, 12.46, 14.61, 17.06, 25.43, 26.67, 
29.11, 32.48, 44.96, 67.87, 114.95, 127.78, 129.44, 130.10, 132.60, 138.43, 140.0, 153.46, 159.47.  
 
4.3 Synthesis of Compound 3 
 
Compound 2 (190 mg, 0.34 mmol) was dissolved in 20 ml DMSO. Excess amount of sodium 
azide (600 mg, 9.23 mmol) was added. The reaction mixture was stirred for 30 minutes at 60
o
C. After 30 
minutes, sample was extracted with water and CHCl3 a few times to get rid of DMSO and excess NaN3. 
Organic layer containing compound 3 was dried with Na2SO4 and evaporated under reduced pressure No 
further purification was required. 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52 Hz, 6H), 1.35 (s, 6H), 1.54 (m, 4H), 1.68 (m, 2H), 
1.85 (m, 2H), 2.3 (q, J= 7.56 Hz,  4H), 2.55 (s, 6H), 3.32 (t, J= 6.64 Hz, 2H),  4.05 (t, J= 6.45 Hz, 2H), 
7.0 (d, J= 8.56 Hz, 2H), 7.15 (d, J= 8.56 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, δ ppm) 11.84, 12.46, 
14.62, 17.07, 25.71, 26.56, 28.80, 29.13, 51.38, 67.86, 114.95, 127.77, 129.44, 131.19, 132.61, 138.43, 
140.33, 153.46, 159.46. HRMS-ESI: calculated for M+H 522.3216, found 522.3240, ∆= 0.8 ppm.  
 
4.4 Synthesis of Compound 4 
 
5-(hydroxymethyl)benzene-1,3-diol (5 g, 35.7 mmol) was dissolved in 200 ml acetone in round 
bottom flask. K2CO3 (5 g, 35.7 mmol) and catalytic amount of 18-crown-6 were added. Propargyl 
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bromide (10.5 g, 71.4 mmol) was added to the flask and the reaction mixture was refluxed for 24h. Then, 
acetone was evaporated in vacuo and extracted with water and chloroform. Organic layer was dried with 
Na2SO4 and evaporated in vacuo. The product was purified by silica gel column chromatography using 
CHCl3/Methanol (97:3, v/v). Fraction containing compound 4 was collected then the solvent was 
removed under reduced pressure (30.5 mmol, 6.6 g, 86% ). 
1
H NMR (CDCl3, 400 MHz, δ ppm) 2.45 (s, 2H), 4.60 (s, 6H), 6.49 (s, 1H), 6.51 (s, 2H). 
13
C NMR 
(CDCl3, 100 MHz, δ ppm) 55.92, 65.12, 75.67, 78.37, 101.52, 106.23, 143.59, 158.86 as reported 
elsewhere.
4 
 
4.5 Synthesis of Compound 5 
 
Compound 4 (1 g, 4.625 mmol) was dissolved in 50 ml dichloromethane. Pyridinium 
chlorochromat (2 g, 9.25 mmol) was added and the reaction mixture was stirred at room temperature. 
After 15 minutes all of the compound 4 was converted to compound 5 as followed by TLC. 
Dichloromethane was evaporated in vacuo  and the product was purified by silica gel column 
chromatography using CHCl3 as mobile phase. Fraction containing compound 5 was collected then the 
solvent was removed under reduced pressure. 
1
H NMR (CDCl3, 400 MHz, δ ppm) 2.58 (t, J=2.36 Hz, 2H), 4.73 (d, J=2.40 Hz, 4H), 6.85 (t, J= 2.32 Hz, 
1H), 7.1 (d, J=2.36 Hz, 2H), 9.9 (s, 1H). 
13
C NMR (CDCl3, 100 MHz, δ ppm) 56.15, 76.27, 77.78, 108.8, 
138.39, 159.09, 191.42.   
 
4.6 Synthesis of Compound 6 
 
CH2Cl2 (300 ml) was purged with Ar for 30 minutes. Compound 5 (1.0 g, 4.6 mmol) and 2,4-
dimethyl pyrrole (1.141 g, 9.2 mmol) were added. The color of the solution turned into red after the 
addition of 3 drops of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 12h. 
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Then, tetrachloro-1,4-benzoquinone (1.12 g, 4.6 mmol) was added and the reaction mixture was stirred at 
room temperature for 45 min. Then triethyl amine (8 ml) and boron trifluoride diethyl etherate (8 ml) 
were added sequencially. After stirring at room temperature for 30 min, it was extracted with water. 
Organic layer was dried with Na2SO4 and evaporated under reduced pressure. The product was purified 
by silica gel column chromatography using CHCl3: Hexane (66:33, v/v) as mobile phase. Fraction 
containing compound 6 was collected then the solvent was removed under reduced pressure (470 mg, 
0.96 mmol, 21% ). 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.48 Hz,  6H), 1.44 (s, 6H), 2.3 (q, J=7.56 Hz, 4H), 2.5-
2.55 (m, 6H+2H), 4.69 (d, J=2.08 Hz, 4H), 6.6 (d, J=2.28 Hz, 2H), 6.7 (t, J=2.28 Hz, 1H). 
13
C NMR 
(CDCl3, 100 MHz, δ ppm) 11.54, 12.50, 14.63, 17.07, 56.04, 75.94, 78.10, 103.50, 107.93, 130.39, 
132.80, 137.56, 138.40, 139.18, 153.89, 159.35. HRMS-ESI: calculated for M+Na 489.2525, found 
489.2509, ∆= -3.2 ppm.  
4.7 Synthesis of Compound 7 
 
Compound 1 (72 mg, 0.25 mmol) and compound 6 (122 mg, 0.25 mmol) were dissolved in 
benzene (45 ml). Piperidine (0.2 ml) and glacial acetic acid (0.2 ml) were added. The solution was 
refluxed using Dean-Stark apparatus. When the solution was concentrated, reaction was followed by TLC 
until purple-colored product became the major product. Then, benzene was evaporated in vacuo. It was 
extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated under reduced 
pressure. The product was purified by silica gel column chromatography using Ethyl Acetate: Hexane 
(25:75, v/v) as mobile phase. Fraction containing compound 7 was collected then the solvent was 
removed under reduced pressure (78 mg, 0.1 mmol, 29% ). 
 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 6.48 Hz,  3H), 1.18 (t, J= 7.56 Hz), 1.45-1.55 (m, 3H + 3H 
+ 4H), 1.82 (m, 4H), 2.33 (q, J=7.52 Hz, 2H), 2.5-2.65 (m, 3H + 2H + 2H), 3.6 (t, J= 6.68 Hz, 2H), 4.05 (t, 
J= 6.44 Hz, 2H), 4.69 (s, 4H), 6.6 (d, J=2.32 Hz, 2H), 6.7 (t, J=2.32 Hz, 1H), 6.9 (d, J= 8.6 Hz, 2H), 7.19 
(d, J= 16.69 Hz, 1H), 7.5 (d, J= 8.72 Hz, 2H), 7.62 (d, J= 16.72 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz, 
δ ppm) 11.27, 11,61, 12.75, 14.10, 14.56, 17.12, 18.33, 25.41, 26.66, 29.08, 30.32, 32.52, 44.99, 56.07, 
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67.84, 75.91, 78.09, 103.57, 108.14, 114.74, 117.89, 128.61, 130.19, 135.00, 137.73, 159.35, 159.58. 
HRMS-ESI: calculated for M+Na 755.2831, found 755.2811, ∆= 2.6 ppm.  
 
 
 
4.8 Synthesis of Compound 8  
Compound 1 (1.5 g, 5.3 mmol) was dissolved in 25 ml DMSO. Sodium azide (1.37 g, 21.2 mmol) 
was added and the reaction mixture was stirred at 60
o
C for 2.5 hours. Then, it was extracted with water 
and CHCl3 a few times and organic layer was collected, dried with Na2SO4 and evaporated under reduced 
pressure. No further purification was required.  
 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.4-1.55 (m, 4H), 1.55-1.65 (m, 2H), 1.75-1.85 (m, 2H), 3.28 (t, 
J=6.80 Hz, 2H), 4.05 (t, J=6.40 Hz, 2H), 7.00 (d, J=8.76 Hz, 2H ), 7.82 (d, J= 7.86 Hz, 2H), 9.86 (s, 1H). 
13
C NMR (CDCl3, 100 MHz, δ ppm) 25.57, 26.43, 28.74, 28.89, 51.31, 68.12, 114.73, 129.80, 131.96, 
164.14, 190.75. HRMS (TOF-ESI): m/z calcd for C13H17N3O2: 248.13990 [M+H]
+
; found: 248.14573 
[M+H]
+
, ∆ = 23.5 ppm.  
 
4.9 Synthesis of Compound 9 
 
CH2Cl2 (300 ml) was purged with Ar for 30 min. 4-methoxy benzaldehyde (394 mg, 2.89 mmol) 
and 2,4-dimethyl pyrrole (0.75 g, 5.78 mmol) were added. The color of the solution turned into red after 
the addition of 3 drops of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 
12h. Then, tetrachloro-1,4-benzoquinone (0.72 g, 2.89 mmol) was added and the reaction mixture was 
stirred at room temperature for 45 min. Then triethyl amine (6 ml) and boron trifluoride diethyl etherate 
(6 ml) were added sequencially. After stirring at room temperature for 30 min, it was extracted with water. 
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Organic layer was dried with Na2SO4 and evaporated under reduced pressure. The product was purified 
by silica gel column chromatography using CHCl3 as mobile phase. Fraction containing compound 9 was 
collected then the solvent was removed under reduced pressure (412 mg, 1 mmol, 35% ). 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52 Hz,  6H), 1.35 (s, 6H), 2.3 (q, J=7.56 Hz, 4H), 2.52 (s, 
6H), 3.90 (s, 3H), 7.00 (d, J=8.76 Hz, 2H), 7.16 (d, J= 8.76 Hz, 2H), 
13
C NMR (CDCl3, 100 MHz, δ ppm) 
11.81, 12.46, 14.61, 17.06, 55.30, 114.42, 127.87, 129.46, 131.19, 132.62, 138.43, 140.27, 153.48, 159.99.  
HRMS-ESI: calculated for M+H 411.2419, found 411.2424, ∆= 0.2 ppm.  
 
4.10 Synthesis of Compound 10 
 4-hydroxybenzaldehyde (4.9 g, 40 mmol) and propargyl bromide (5 g, 60 mmol) were dissolved in 
100 ml acetonitrile. K2CO3 (11 g, mmol) and a few crystals of benzo-18-crown-6 were added. The 
reaction was refluxed until all 4-hydroxybenzaldehyde was consumed. The solvent was evaporated, 
extracted with water and CHCl3. Organic layer was dried with Na2SO4 and evaporated under reduced 
pressure. The product was purified by silica gel column chromatography using CHCl3/Hexane (50:50, 
v/v). Fraction containing compound 10 was collected then the solvent was removed under reduced 
pressure (5.8 g, 91%). 
 
1
H NMR (CDCl3, 400 MHz, δ ppm) 9.92 (s, 1H), 7.87 (d, J=8.92 Hz, 2H), 7.11 (d, J=8.72 Hz, 2H), 4.80 
(d, J=2.44 Hz, 2H), 2.58 (t, J=2.48 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz, δ ppm) 55.94, 76.35, 77.54, 
115.18, 130.00, 131.88, 162.37, 190.74. HRMS-ESI: calculated for M+Na 183.0422, found 183.0422, ∆= 
0 ppm. 
 
 
 
4.11 Synthesis of Compound 11 
Compound 9 (100  mg, 0.24 mmol) and Compound 10 (98 mg, 0.6 mmol) dissolved in benzene 
(45 ml). Piperidine (0.4 ml) and glacial acetic acid (0.4 ml) were added. The solution was refluxed using 
Dean-Stark apparatus. When the solution was concentrated, reaction was followed by TLC until green-
colored product became the major product. Then, benzene was evaporated in vacuo. It was extracted with 
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CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated under reduced pressure. The 
product was purified by silica gel column chromatography using Ethyl Acetate:Hexane (25:75, v/v) as 
mobile phase. Fraction containing compound 11 was collected then the solvent was removed under 
reduced pressure (150 mg, 0.22 mmol, 90% ). 
 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.15 (t, J= 7.48 Hz,  6H), 1.38 (s, 6H), 2.55-2.65 (m, 4H+2H ), 3.90 
(s, 3H), 4.75 (d, J=2.36 Hz, 4H), 7.00-7.06 (m, 4H + 2H), 7.17-7.24 (m, 2H+2H), 7.06 (d, J=8.76 Hz, 4H), 
7.70 (d, J=16.56 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, δ ppm) 11.67, 14.04, 18.00, 55.58, 56.04, 75.50, 
78.10, 115.20, 116.00, 118.50, 127.50, 128.69, 129.50, 130.00, 133.50, 158.00, 159.50. HRMS-ESI: 
calculated for M+Na 717.3076, found 717.3060, ∆= -2.2 ppm.  
 
4.12 Synthesis of Compound 12 
 
Compound 6 (200  mg, 2.05 mmol) and compound 10 (800.9 mg, 5 mmol) dissolved in benzene 
(45 ml). Piperidine (0.5 ml) and glacial acetic acid (0.5 ml) were added. The solution was refluxed using 
Dean-Stark apparatus. When the solution was concentrated, reaction was followed by TLC until green-
colored product became the major product. Then, benzene was evaporated in vacuo. It was extracted with 
CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated under reduced pressure. The 
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product was purified by silica gel column chromatography using Ethyl Acetate:Hexane (20:80, v/v) as 
mobile phase. Fraction containing compound 12 was collected then the solvent was removed under 
reduced pressure. 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.15 (t, J= 7.44 Hz,  6H), 1.5 (s, 6H), 2.52 (t, J=2.36 Hz, 2H), 2.55 (t, 
J=2.36 Hz, 2H), 2.63 (q, J=7.56 Hz, 4H), 4.70 (d, J=2.4 Hz, 4H), 4.75 (d, J= 2.36 Hz, 4H), 6.63 (d, J=2.32 
Hz, 2H), 6.72 (t, J=2.28 Hz, 1H), 7.05 (d, J=8.80 Hz, 4H), 7.21 (d, J=16.77 Hz, 2H), 7.60 (d, J=8.80 Hz, 
4H), 7.68 (d, J= 16.73 Hz, 2H).  
13
C NMR (CDCl3, 100 MHz, δ ppm) 11.37, 14.04, 18.39, 55.89, 56.08, 
75.73, 75.94, 78.10, 103.61, 108.32, 115.22, 118.58, 128.73, 130.00, 131.17, 135.26, 137.86, 158.04, 
159.37. HRMS-ESI: calculated for M+Na 795.3182, found 795.3199, ∆= 2.2 ppm.  
 
 
 
 
4.13 Synthesis of Compound 13 
 
Compound 9 (410 mg, 1 mmol) and 4-(6-azidohexoxy) benzaldehyde 8 (120 mg, 0.49 mmol) 
dissolved in benzene (45 ml). Piperidine (0.5 ml) and glacial acetic acid (0.5 ml) were added. The 
solution was refluxed using Dean-Stark apparatus. When the solution was concentrated, reaction was 
followed by TLC until purple-colored product became the major product. Then, benzene was evaporated 
in vacuo. It was extracted with CHCl3 and water. Organic layer was taken, dried with Na2SO4 and 
evaporated under reduced pressure. The product was purified by silica gel column chromatography using 
Ethyl Acetate:Hexane (20:80, v/v) as mobile phase. Fraction containing 13 was collected then the solvent 
was removed under reduced pressure (100 mg, 0.16 mmol, 16 %) 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.48 Hz,  3H), 1.15 (t, J= 7.56 Hz, 3H), 1.36 (s, 3H), 1.38 
(s, 3H), 1.50 (m, 4H), 1.68 (m, 2H), 1.84 (m, 2H), 2.34 (q, J= 7.48 Hz, 2H), 2.58 (m, 2H+3H), 3.32 (t, J= 
6.84 Hz, 2H), 3.90 (s, 3H), 4.02 (t, J=6.32 Hz, 2H), 6.91 (d, J=8.72 Hz, 2H), 7.03 (d, J=8.68 Hz, 2H), 
7.15-7.22 (m, 2H+1H), 7.54 (d, J=8.76 Hz, 2H), 7.62 (d, J=16.69 Hz, 1H) 
13
C NMR (CDCl3, 100 MHz, 
δ ppm) 11.58, 11.91, 12.71, 14.11, 14.56, 17.11, 18.32, 25.68, 26.52, 28.81, 29.11, 51.40, 55.33, 67.81, 
114.44, 114.72, 118.00, 128.03, 128.57, 129.65, 130.27, 134.73, 138.63, 149.90, 155.00, 159.49, 160.02. 
HRMS-ESI: calculated for M+Na 640.3634, found 640.3604, ∆= -4.8 ppm.  
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4.14 Synthesis of Compound 14  
Synthesis was done according to literature.
5
 Compound 3 (107 mg, 0.21 mmol) and compound 7 (78 mg, 
0.1 mmol) were dissolved in 8 ml THF. A few drops of Et3N was added and the reaction mixture was 
stirred for 5 minutes at room temperature. In a viel, CuSO4.5H2O (30% mole equavalent of compound 7, 
7.5 mg, 0.03 mmol) was dissolved in 4 ml water separately. Sodium ascorbate (60% mole equavalent of 
compound 7, 11.88 mg, 0.06 mmol) was dissolved in 4 ml water in another viel. Solutions of sodium 
ascorbate and CuSO4 were added to the first reaction mixture sequantially and the resultant mixture was 
stirred at room temperature untill all compound 7 was consumed, as followed by TLC. Then, it was 
extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated  under reduced 
pressure. The product was purified by silica gel column chromatography using  CHCl3 as mobile phase. 
Fraction containing compound 14 was collected then the solvent was removed under reduced pressure (65 
mg, 0.035mmol, 35 % ). 
 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (m, 15H), 1.16 (t, J= 7.40 Hz, 3H), 1.34 (s, 12H), 1.42-1.62 (m, 
3H + 3H + 12H), 1.84 (m, 8H), 2.00 (m, J= 8H), 2.3 (m, 8H + 2H), 2.54 (s, 12H), 2.58-2.64 (m, 2H+3H), 
3.58 (t, J=6.68 Hz, 2H), 4.01 (m, 6H), 4.42 (t, J=7.12 Hz, 4H), 5.20 (s, 4H), 6.61 (d, J=2.20, 2H), 6.78 (t, 
J=2.20 Hz, 1H), 6.90 (d, J= 8.76 Hz, 2H), 6.98 (d, J=8.60 Hz, 4H), 7.15 (d, J=8.52, 4H), 7.19 (d, 
J=16.286 Hz, 1H), 7.54 (d, J=8.72 Hz, 2H), 7.61 (d, J=16.85 Hz, 1H), 7.66 (s, 2H). 
13
C NMR (CDCl3, 
100 MHz, δ ppm) 11.32, 11.66, 11.85, 12.46, 14.10, 14.57, 14.62, 17.06, 25.40, 25.61, 26.37, 26.66, 
29.08, 30.25, 32.51, 44.99, 50.36, 62.27, 67.75, 67.84, 100.00, 102.00, 108.00, 114.75, 114.91, 122.64, 
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127.83, 128.61, 129.46, 130.13, 132.62, 135.05, 137.86, 138.40, 140.27, 143.44, 153.49, 159.41, 160.22.  
MALDI: calculated for compound 14 1782.8871, found 1755. 
 
4.15 Synthesis of Compound 15 
Compound 14 (40 mg, 0.022 mmol) and sodium azide (7.23 mg, 0.11 mmol) was dissolved in 15 
ml acetonitrile. Catalytic amount of 18-crown-6 was added and the reaction mixture was stirred 2 days at 
60
o
C. Then, it was extracted with ethyl acetate and water. Organic layer was collected, dried with Na2SO4 
and evaporated under reduced pressure. No further purification was required. Compound 15 was used 
immediately after synthesized.  
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (m, 15H), 1.16 (t, J= 7.16 Hz, 3H), 1.34 (s, 12H), 1.42-1.62 (m, 
3H + 3H + 12H), 1.84 (m, 8H), 2.00 (m, 8H), 2.3 (m, 8H + 2H), 2.50-2.65 (m, 12H+2H+3H), 3.30 (t, 
J=6.84 Hz, 2H), 4.05 (m, 6H), 4.42 (t, J=7.12 Hz, 4H), 5.20 (s, 4H), 6.61 (d, J=1.68, 2H), 6.78 (t, J=2.20 
Hz, 1H), 6.90 (d, J= 8.56 Hz, 2H), 6.98 (d, J=8.28 Hz, 4H), 7.15-7.20 (m,4H+1H), 7.54 (d, J=8.60 Hz, 
2H), 7.61 (d, J=16.53 Hz, 1H), 7.66 (s, 2H).  
 
 
4.16 Synthesis of Compound 16  
Compound 11 (22 mg, 0.03 mmol) and compound 13 (60 mg, 0.094 mmol) were dissolved in 3 ml 
THF. A few drops of Et3N was added and the reaction mixture was stirred for 5 minutes at room 
temperature. In a viel, CuSO4.5H2O (30% mole equavalent of compound 11, 2.3 mg, 0.009 mmol) was 
dissolved in 1.5 ml water separately. Sodium ascorbate (60% mole equavalent of compound 11, 3.6 mg, 
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0.018 mmol) was dissolved in 1.5 ml water in another viel. Solutions of sodium ascorbate and CuSO4 
were added to the first reaction mixture sequantially and the resultant mixture was stirred at room 
temperature untill all compound 11 was consumed, as followed by TLC. Then, it was extracted with 
CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated  under reduced pressure. The 
product was purified by silica gel column chromatography using CHCl3:Methanol (95:5, v/v)  as mobile 
phase. Fraction containing compound 16 was collected then the solvent was removed under reduced 
pressure. 
 
 
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (t, J= 7.52 Hz,  6H), 1.15 (M, 12H), 1.35 (m, 12H+6H+2H), 1.54 
(m, 4H), 1.78 (m, 4H), 1.98 (m, 4H), 2.32 (m, 4H), 2.55-2.65 (m, 6H+8H), 3.9 (s, 9H), 3.98 (t, J= 6.20 Hz, 
4H), 4.4 (m, 4H), 5.3 (s, 4H), 6.88 (d, J= 8.80 Hz, 4H), 7.03 (m, 4H+2H+4H), 7.12-7.24 (m, 4H+2H+4H), 
7.52 (d, J= 8.72 Hz, 4H), 7.55-7.65 (m, 2H+4H+2H), 7.68 (d, J= 16.61 Hz, 2H) 
13
C NMR (CDCl3, 100 
MHz, δ ppm) 11.91, 12.72, 14.06, 14.11, 14.57, 17.11, 18.32, 18.38, 25.50, 26.23, 28.97, 30.19, 50.33, 
55.33, 62.19, 67.68, 114.44, 114.47, 114.72, 115.15, 122.58, 128.02, 128.55, 128.77, 129.65, 129.85, 
130.24, 130.86, 134.73, 158.72, 159.47, 160.02, 160.06. MALDI: calculated for compound 16 1973.0291, 
found 1973. 
 
4.17 Synthesis of Compound 17  
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Compound 12 (13.3 mg, 0.017 mmol) and compound 13 (55 mg, 0.086 mmol) were dissolved in 3 
ml THF. A few drops of Et3N was added and the reaction mixture was stirred for 5 minutes at room 
temperature. In a viel, CuSO4.5H2O (21.5 mg, 0.086 mmol) was dissolved in 1.5 ml water separately. 
Sodium ascorbate (25.6 mg, 0.129 mmol) was dissolved in 1.5 ml water in another viel. Solutions of 
sodium ascorbate and CuSO4 were added to the first reaction mixture sequantially and the resultant 
mixture was stirred at room temperature untill all compound 12 was consumed, as followed by TLC. 
Then, it was extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated under 
reduced pressure. The product was purified by silica gel column chromatography using CHCl3 as mobile 
phase and then CHCl3:Methanol (98:2, v/v) as mobile phase. Fraction containing compound 17 was 
collected then the solvent was removed under reduced pressure.   
1
H NMR (CDCl3, 400 MHz, δ ppm) 0.8-1.65 (m, 24H+24H+8+8+8+6+6), 1.75 (m, 8H), 1.95 (m, 8H), 
2.32 (m, 8H), 2.6 (m, 20H+4H), 3.9 (s, 12H), 4.00 (m, 8H), 4.40 (m, 8H), 5.2 (m, 8H), 6.6 (d, J= 3.84 Hz, 
2H), 6.9 (m, 8H+4H+1H), 7.00 (m, 8H+4H), 7.1-7.25 (m, 8H+ 4H + 2H), 7.45-7.70 (m, 
4H+8H+2H+4H+4H).  MALDI: calculated for compound 17, 3329.7508, found 3329. 
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4.18 Synthesis of Compound 18 
Compound 12 (4.39 mg, 0.0057 mmol) and compound 15 (50 mg, 0.028 mmol) were dissolved in 
3 ml THF. A few drops of Et3N was added and the reaction mixture was stirred for 5 minutes at room 
temperature. In a viel, CuSO4.5H2O (19 mg, 0.076 mmol) was dissolved in 0.75 ml water separately. 
Sodium ascorbate (35.1 mg, 0.177 mmol) was dissolved in 0.75 ml water in another viel. Solutions of 
sodium ascorbate and CuSO4 were added to the first reaction mixture sequantially and the resultant 
mixture was stirred at room temperature untill all compound 12 was consumed, as followed by TLC. 
Then, it was extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated under 
reduced pressure. The product was purified by silica gel column chromatography using CHCl3: Methanol 
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(95:5, v/v) as mobile phase. Fraction containing compound 18 was collected then the solvent was 
removed under reduced pressure.   
1
H NMR (CDCl3, 400 MHz, δ ppm) 1.0 (m, 60H), 1.18 (m, 12H+6H), 1.22-1.70 (m, 120H + 6H + 8H), 
1.82 (m, 32H), 2.00 (m, 24H), 2.34 (m, 40H), 2.5-2.64 (m, 12H+8H+48H+4H), 4.00 (m, 16H+8H), 4.40 
(m, 16H+8H), 5.2 (m, 16H+8H), 6.6 (8H+2H), 6.79 (4H+1H), 6.86 (8H), 7.00(16H+4H), 7.18 
(16H+4H+2H), 7.48-7.62 (8H+4H+4H+2H), 7.65 (8H+4H). MALDI: calculated for compound 18, 
7812.3031, found 7794.  
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5. Preparation of Dendrimer-doped Epoxy Resin 
 Epoxy resin (25.0 g, Specifix) was taken; dendrimer in acetone was added to the resin with final 
concentration 2.5 µM. Following the addition of hardener (3.0 g) the sample was stirred rigorously for a 
few minutes and then poured into a small container. It was dried in vacuo until all bubbles have 
disappeared. Then samples were left overnight and sliced into mm-sized cylindrical slabs.  
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7. !MR Spectra 
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C spectra of Compound 1.  
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C spectra of Compound 3. 
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C NMR spectra of Compound 8.  
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C NMR spectra of Compound 9.  
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H NMR spectra of Compound 10.  
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H and 
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C NMR spectra of Compound 11.  
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H and 
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C NMR spectra of Compound 12.  
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1
H and 
13
C NMR spectra of Compound 13.  
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1
H and 
13
C NMR spectra of Compound 14.  
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1
H NMR spectra of Compound 15. 
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1
H and 
13
C NMR spectra of Compound 16. 
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Figure 34. 
1
H NMR spectra of Compound 17. 
 
 
 
 
 
 
 
 
 
 
Figure. 
1
H and 
13
C NMR spectra of Compound. (53) 
 
 
 
 
 
 
 
 
 
 
1
H NMR spectra of Compound 18. 
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8. MASS Spectra 
 
 
 ESI-HRMS of compound 1. 
 
 ESI-HRMS of compound 3. 
 
 
 ESI-HRMS of compound 6. 
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 ESI-HRMS of compound 7. 
 
 
 ESI-HRMS of compound 8. 
 
 
 ESI-HRMS of compound 9. 
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 ESI-HRMS of compound 10. 
 
 
 ESI-HRMS of compound 11. 
 
 
 
 ESI-HRMS of compound 12. 
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 ESI-HRMS of compound 13. 
 
 
 MALDI-MS of compound 14. 
 
 
 MALDI-MS of compound 16. 
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 MALDI-MS of compound 17. 
 
 
 
 MALDI-MS of compound 18. 
 
 
